Immunotherapy during surgery? Surge Therapeutics nabs $32M to expand clinical plans after first dosing
Weeks ago, Surge Therapeutics marked what CEO Michael Goldberg hopes will go down in history as a turning point in cancer care: the first time a patient received an immunotherapy, in the form of a hydrogel, at the site of their tumor during surgery.
Now, the Cambridge, MA-based biotech has raised $32 million in a Series B to fund that trial while bringing to the clinic two more candidates with the same approach, which it calls intraoperative immunotherapy.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.